Clinical Trials Directory

Trials / Completed

CompletedNCT01740245

Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
Sponsor
AGUNCO Obstetrics and Gynecology Centre · Academic / Other
Sex
Female
Age
20 Years – 40 Years
Healthy volunteers
Not accepted

Summary

Treatments for the macroscopic or pathologic lesions caused by HPV infection can be classified as topical, surgical, destructive, or immunomodulatory. Post surgical treatments generally consist of analgesic, anti-inflammatory and topical antimicrobial agents to reduce the risk of local infections. The aim of this study is to compare the efficacy and safety of polyhexamethylene biguanide-based vaginal suppositories to a similar chlorhexidine-based treatment, in the post recovery regimen after surgical treatment of cervical lesions. Women who underwent to CO2 laser therapy for cervical lesions are randomly assigned to receive 10 days of antiseptic treatment with chlorhexidine digluconate vaginal suppositories, or polyhexamethylene biguanide vaginal suppositories (Monogin® / BiguanelleTM vaginal suppositories, Lo.Li.Pharma, Italy). A weekly follow-up check was performed for 6 weeks.

Conditions

Interventions

TypeNameDescription
DEVICEChlorhexidine vaginal suppositories
DEVICEPolyhexamethylene biguanide vaginal suppositories

Timeline

First posted
2012-12-04
Last updated
2012-12-04

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT01740245. Inclusion in this directory is not an endorsement.